EcoDrugPlus

Oxytocin Receptor

Ensembl ID : ENSPTRG00000014582
Gene Symbol: OXTR
5 Cross references
262 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSPTRG00000006915
Gene Symbol: PAK4
5 Cross references
163 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pancreatic Lipase

Ensembl ID : ENSPTRG00000002970
Gene Symbol: PNLIP
5 Cross references
300 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSPTRG00000014861
Gene Symbol: PTH1R
5 Cross references
196 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Peptidylprolyl Isomerase A

Ensembl ID : ENSPTRG00000046562
Gene Symbol: PPIA
5 Cross references
299 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSPTRG00000014505
Gene Symbol: PPARA
5 Cross references
453 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSPTRG00000018082
Gene Symbol: PPARD
5 Cross references
418 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSPTRG00000014632
Gene Symbol: PPARG
5 Cross references
405 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSPTRG00000015642
Gene Symbol: PIK3CA
4 Cross references
275 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSPTRG00000015452
Gene Symbol: PIK3CB
5 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSPTRG00000000120
Gene Symbol: PIK3CD
5 Cross references
213 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSPTRG00000019573
Gene Symbol: PIK3CG
5 Cross references
213 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).